Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics

Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1-targeted medicines for obesity like Wegovy and Zepbound. Both companies have a plausible pathway to continue making their investors wealthier, perhaps by quite a bit.But which one is a better stock to buy right now? Join me in analyzing each, and we'll figure it out together.Of the two companies, Viking Therapeutics is slightly closer to reaching the market. Its lead candidate, VK2735, has already reported some great data from its phase 2b clinical trial, and there might be more on the way.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool